

GLAXOSMITHKLINE PLC
 Form 6-K
 February 21, 2017

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Sir Andrew Witty
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

 - a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|----------|-------------------|
| £0.0000 | 67,867 (Deferred) |
| £0.0000 | 22,621 (Matching) |

- Aggregated information
- d) Aggregated volume Price 90,448
£0.0000
 - e) Date of the transaction 2017-02-20
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Sir Andrew Witty
 - b) Position/status Chief Executive Officer

- c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-------------------|
| £16.3353 | 31,898 (Deferred) |
| £16.3353 | 10,633 (Matching) |

- Aggregated information
- d) Aggregated volume Price 42,531
£16.3353
- e) Date of the transaction 2017-02-20
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms E Walmsley
- b) Position/status CEO Designate
- c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

| | |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| b) Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £0.0000 14,860 (Deferred) £0.0000 4,954 (Matching) |
| d) Aggregated information | |
| d) Aggregated volume Price | 19,814 £0.0000 |
| e) Date of the transaction | 2017-02-21 |
| f) Place of the transaction | n/a |

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status CEO Designate
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 - a) Description of the financial instrument

- b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred

| | |
|-----------------------------|------------------------------------------------------------|
| | Annual Bonus Plan – Deferred Bonus and Matching Awards. |
| | Price(s) Volume(s) |
| c) Price(s) and volume(s) | £16.3500 6,986 (Deferred) £16.3500 2,330 (Matching) |
| | Aggregated information |
| d) Aggregated volume Price | 9,316 £16.3500 |
| e) Date of the transaction | 2017-02-21 |
| f) Place of the transaction | London Stock Exchange (XLON) |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
| 1. Details of PDMR/person closely associated with them ('PCA') | |
| a) Name | Mr D S Redfern |
| b) Position/status | Chief Strategy Officer |
| c) Initial notification/ amendment | Initial Notification |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | Ordinary shares of 25 pence each ('Ordinary Shares') |
| a) Description of the financial instrument | ISIN: GB0009252882 |

| | |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| b) Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards. |
| | Price(s) Volume(s) |
| c) Price(s) and volume(s) | £0.0000 12,115 (Deferred) £0.0000 4,039 (Matching) |
| | Aggregated information |
| d) Aggregated volume Price | 16,154 £0.0000 |
| e) Date of the transaction | 2017-02-20 |
| f) Place of the transaction | n/a |

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D S Redfern
 - b) Position/status Chief Strategy Officer
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
 - c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|----------|------------------|
| £16.3425 | 5,809 (Deferred) |
| £16.3450 | 1,937 (Matching) |
 - d) Aggregated information

| | |
|-------------------|----------|
| Aggregated volume | 7,746 |
| Price | £16.3431 |
 - e) Date of the transaction 2017-02-20
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms C Thomas
 - b) Position/status SVP, Human Resources
 - c) Initial notification/ amendment Initial Notification
- 2.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|------------------|
| £0.0000 | 7,517 (Deferred) |
| £0.0000 | 2,506 (Matching) |

Aggregated information

- d) Aggregated volume Price 10,023
£0.0000
- e) Date of the transaction 2017-02-20
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
 b) Position/status SVP, Human Resources
 c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

| | |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| b) Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £16.3700 3,604 (Deferred) £16.3550 1,202 (Matching) |
| d) Aggregated information | |
| d) Aggregated volume Price | 4,806 £16.3662 |
| e) Date of the transaction | 2017-02-20 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr P C Thomson
 - b) Position/status SVP, Communications & Government Affairs
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

 - a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and

Matching Awards.

| | Price(s) | Volume(s) |
|---------------------------|----------|------------------|
| c) Price(s) and volume(s) | £0.0000 | 4,528 (Deferred) |
| | £0.0000 | 1,509 (Matching) |

Aggregated information

| | |
|-----------------------------|------------|
| d) Aggregated volume Price | 6,037 |
| | £0.0000 |
| e) Date of the transaction | 2017-02-20 |
| f) Place of the transaction | n/a |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|------------------------------------|------------------------------------------|
| a) Name | Mr P C Thomson |
| b) Position/status | SVP, Communications & Government Affairs |
| c) Initial notification/ amendment | Initial Notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

| | |
|--------------------------------------------|--------------------|
| a) Description of the financial instrument | ISIN: GB0009252882 |
|--------------------------------------------|--------------------|

| | |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| b) Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards. |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| | Price(s) | Volume(s) |
|---------------------------|----------|------------------|
| c) Price(s) and volume(s) | £16.3450 | 2,171 (Deferred) |
| | £16.3500 | 724 (Matching) |

Aggregated information

| | |
|----------------------------|----------|
| d) Aggregated volume Price | 2,895 |
| | £16.3462 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- e) Date of the transaction 2017-02-20
- f) Place of the transaction London Stock Exchange
(XLON)